Interventional Platform Articles & Analysis
14 news found
EZ Glide, the most recent enhancement to Lumendi’s DiLumen Endoluminal Interventional Platform (EIP), has achieved significant quarter-over-quarter product sales since its market introduction in Q4 2020, and is on track to double the sales revenue from the prior year. ...
This Series B financing round includes € 25 million from the cardiovascular-focused medical device platform company MitrAssist Holdings Limited accompanied by an additional € 4 million from the returning investor Maurizio Group. ...
The Percutaneous Coronary Interventions (PCI) were performed on April 8 and 13 by Prof. Stefan Verheye, a recognized and highly experienced interventional cardiologist at ZNA Middelheim hospital in Antwerp, and his team. Robotic-assisted PCI has never been done before in this country. R-One is a robotic platform that assists ...
ByRobocath
Investor Webcast: The DiLumen platform and EZ Glide will be discussed in a webcast on March 31, 2021. ...
Connecticut-based medical device innovator Lumendi, LLC has announced a change in the company’s Mission & Vision statements to better communicate the intended path of its innovative DiLumenTM Endolumenal Interventional Platform (EIP) to transform the GI landscape from surgical intervention to endolumenal. ...
Patient reported no post-procedure pain and resumed regular activity day after procedure Connecticut-based medical device innovator Lumendi, LLC reports the first endoscopic appendectomy using its DiLumenTM Endolumenal Interventional Platform (EIP). A patient underwent the purely endoscopic endolumenal appendectomy to remove a lesion previously ...
Connecticut-based medical device innovator Lumendi LLC reports that its 1:1 randomized trial of the DiLumen Endolumenal Interventional Platform (EIP) successfully met the primary endpoint of an IRB-approved 200-patient prospective study. ...
If the CardiacSense watch detects a heart arrhythmia, cardiac arrest or threshold-crossing blood pressure values, it sends an alert for timely provision of the necessary medical intervention. Integration into the HSC IoT platform will ensure alerts can be appropriately shared with clinicians and other key stakeholders. The CardiacSense solution has the ability ...
Connecticut-based medical device innovator Lumendi, LLC reports that its 1:1 randomized trial of the DiLumen Endoluminal Interventional Platform (EIP) successfully met the primary endpoint of an IRB-approved 200-patient prospective study. ...
The LOBO system combines a patented design with proprietary HDBRAID™ technology to provide interventional physicians with a minimally invasive platform for rapid and focal occlusion of a wide range of arterial targets with a single device. ...
Food and Drug Administration (FDA) to market its SeeFactorCT3 Imaging Platform. SeeFactorCT3 consists of 3 integrated imaging systems: CT, Fluoroscopy and Digital Radiography; a detachable patient table/chair, and sterile drape for interventional procedures. ...
Lumendi also reports that, to date, clinicians in the U.S., several EU countries including Germany, France, Italy, Spain and the U.K., as well as at the Chinese University of Hong Kong, have completed over 1,000 procedures with the commercially available DiLumen™ Endolumenal Interventional Platform (EIP). Three clinical studies using the DiLumen EIP have ...
The new patent is part of an expanding and comprehensive portfolio of patents, patent applications and other intellectual property covering the composition, synthesis, manufacturing, formulations and uses for the treatment of a variety of metastatic bone lesions and osteologic interventions. Zetagen exclusively licensed its platform technology from the State ...
-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions Latest patent issuance furthers the Company’s Global IP strategy Company’s intellectual property pipeline targets other oncologic treatments for Skeletal-Related Events (SRE’s) and osteologic interventions Zetagen Therapeutics, ...